T2 Biosystems (T2 Biosystems) GF Value : $4.51 (As of May. 05, 2024)

View and export this data going back to 2014. Start your Free Trial

What is T2 Biosystems GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-05-05), T2 Biosystems's share price is $3.72. T2 Biosystems's GF Value is $4.51. Therefore, T2 Biosystems's Price-to-GF-Value for today is 0.82.

Based on the relationship between the current stock price and the GF Value, GuruFocus believes T2 Biosystems is Modestly Undervalued.

T2 Biosystems (NAS:TTOO) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

T2 Biosystems's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	3.72	/	4.51
	=	0.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

T2 Biosystems GF Value Related Terms

Thank you for viewing the detailed overview of T2 Biosystems's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

T2 Biosystems (T2 Biosystems) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » T2 Biosystems Inc (NAS:TTOO) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

0A57:UK

Address

101 Hartwell Avenue, Lexington, MA, USA, 02421

Website

https://www.t2biosystems.com

T2 Biosystems Inc provides rapid in vitro diagnostic tests to hospitals and laboratories. The company's core technology is T2 Magnetic Resonance (T2MR) technology, which can detect a variety of molecular targets directly from whole blood. T2MR technology enables the T2Dx system, which is fully automated from patient sample to result for its panels focused on bacterial and fungal infections that could cause sepsis, and its pipeline panel for Lyme disease.

Executives

Cr Group L.p.	10 percent owner	1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii - Parallel Fund (a) L.p.	10 percent owner	C/O CAPITAL ROYALTY L.P., 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii L.p.	10 percent owner	1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii - Parallel Fund B (cayman) L.p.	10 percent owner	1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii (cayman) Lev Aiv I L.p.	10 percent owner	1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii (cayman) Unlev Aiv I L.p.	10 percent owner	1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Michael Terrence Gibbs	officer: General Counsel	12 STONEY BROOK RD., HOPKINTON MA 01748
John M Sprague	officer: Chief Financial Officer	101 HARTWELL AVE., LEXINGTON MA 02421
Sperzel John J Iii	director, officer: See Remarks	61 CRESTVIEW LANE, BRUNSWICK ME 04011
Brett A. Giffin	officer: Chief Commercial Officer	101 HARTWELL AVE., LEXINGTON MA 02421
Alec Barclay	officer: SVP, Operations	101 HARTWELL AVE., LEXINGTON MA 02421
Aparna Ahuja	officer: Chief Medical Officer	101 HARTWELL AVENUE, LEXINGTON MA 02421
Laura Lee Adams	director	101 HARTWELL AVE., LEXINGTON MA 02421
Anthony Pare	officer: Chief Commercial Officer	HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Thierry Bernard	director	101 HARTWELL AVENUE, LEXINGTON MA 02421